Adaptive MR-Guided Stereotactic Radiotherapy is Beneficial for Ablative Treatment of Lung Tumors in High-Risk Locations.

To explore the benefit of adaptive magnetic resonance-guided stereotactic body radiotherapy (MRgSBRT) for treatment of lung tumors in different locations with a focus on ultracentral lung tumors (ULT). A prospective cohort of 21 patients with 23 primary and secondary lung tumors was analyzed. Tumors were located peripherally (N = 10), centrally (N = 2) and ultracentrally (N = 11, planning target volume (PTV) overlap with proximal bronchi, esophagus and/or pulmonary artery). All patients received MRgSBRT with gated dose delivery and risk-adapted fractionation. Before each fraction, the baseline plan was recalculated on the anatomy of the day (predicted plan). Plan adaptation was performed in 154/165 fractions (93.3%). Comparison of dose characteristics between predicted and adapted plans employed descriptive statistics and Bayesian linear multilevel models. The posterior distributions resulting from the Bayesian models are presented by the mean together with the corresponding 95% compatibility interval (CI). Plan adaptation decreased the proportion of fractions with violated planning objectives from 94% (predicted plans) to 17% (adapted plans). In most cases, inadequate PTV coverage was remedied (predicted: 86%, adapted: 13%), corresponding to a moderate increase of PTV coverage (mean +6.3%, 95% CI: [5.3-7.4%]) and biologically effective PTV doses (BED Adaptive MRgSBRT is highly recommendable for ablative treatment of lung tumors whose PTV initially contacts a sensitive OAR, such as ULT. Here, plan adaptation protects the OAR while maintaining best-possible PTV coverage.

Informations de copyright

Copyright © 2022 Regnery, Buchele, Weykamp, Pohl, Hoegen, Eichkorn, Held, Ristau, Rippke, König, Thomas, Winter, Adeberg, Debus, Klüter and Hörner-Rieber.

Déclaration de conflit d'intérêts

JH-R and SK received speaker fees and travel reimbursement from ViewRay Inc. JH-R received travel reimbursement from IntraOP Medical and Elekta Instrument AB and a grant from IntraOP Medical outside the submitted work. SA received grants from Accuray International Sàrl, Merck Serono GmbH and Novocure GmbH outside the submitted work. SA received consulting fees from Accuray International Sàrl and honoraria for lectures/presentations from Accuray International Sàrl and MSD outside the submitted work. SA received travel reimbursements from AstraZeneca outside the submitted work. SA participated on advisory boards for Sanofi Genzyme outside the submitted work. JD received grants from CRI—The Clinical Research Institute GmbH, View Ray Inc., Accuray Incorporated, Accuray International Sàrl, RaySearch Laboratories AB, Vision RT limited, Astellas Pharma GmbH, Astra Zeneca GmbH, Solution Akademie GmbH, Ergomed PLC Surrey Research Park, Merck Serono GmbH, Siemens Healthcare GmbH, Quintiles GmbH, Pharmaceutical Research Associates GmbH, Boehringer Ingelheim Pharma GmbH Co, PTW-Freiburg Dr. Pychlau GmbH, Nanobiotix A.A. and IntraOP Medical outside the submitted work. MT received honoraria for lectures/presentations from AbbVie, AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim, Celgene, Chugai, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and Takeda outside the submitted work. MT received travel reimbursement from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Chugai Pharma, Janssen, Lilly, Merck, MSD, Novartis, Pfizer, Roche and Takeda outside the submitted work. MT received research grants from Bristol-Myers Squibb, Astrazeneca, Roche and Takeda outside the submitted work. MT participated on advisory boards for AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Chugai Pharma, Janssen, Lilly, Merck, MSD, Novartis, Pfizer, Roche and Takeda outside the submitted work. TE received grants from Ruprecht-Karls Universität Heidelberg, Herbert Kienzle Foundation and Else Kröner-Fresenius Foundation and received travel reimbursement from Bristol-Myers Squibb outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.